Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of shares via dividend reinvestment under the Company's ShareReward Plan.
- Transaction Date: July 14, 2016.
- Price: £16.6373 per share.
- Volume: 38 shares.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses a routine acquisition of shares by the CEO following a dividend payment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of a specific executive transaction.
Investor Verification Points
- Verify the identity of the PDMR involved: Sir Andrew Witty, CEO.
- Confirm the transaction was an acquisition via dividend reinvestment, not an open market purchase.
- Note the transaction volume was minimal (38 shares) relative to the company's total share count.
- Check the transaction date (July 14, 2016) against the dividend payment date referenced in the text.